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Abstract
Debate continues as to the usefulness of assessing adenomas for loss of mismatch repair protein
expression to identify individuals with suspected Lynch syndrome. We tested 109 polyps from 69
proven mutation carriers (35 females and 34 males) belonging to 49 Lynch syndrome families. All
polyps were tested by immunohistochemistry for four mismatch repair proteins MLH1, MSH2,
MSH6 and PMS2. Detailed pathology review was performed by specialist gastrointestinal
pathologists. The majority of polyps (86%) were conventional adenomas (n = 94), with 65 tubular
and 28 tubulovillous adenomas and a single villous adenoma. The remaining 15 lesions (14%)
were serrated polyps. Overall, loss of mismatch repair expression was noted for 78/109 (72%) of
polyps. Loss of mismatch repair expression was seen in 74 of 94 (79%) conventional adenomas,
and 4/15 (27%) serrated polyps from mismatch repair gene mutation carriers. In all instances, loss
of expression was consistent with the underlying germline mutation. mismatch repair protein
expression was lost in 27 of 29 adenomas with a villous component compared with 47 of 65
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adenomas without this feature (93% vs 73%; p=0.028). A strong trend was observed for high-
grade dysplasia. mismatch repair deficiency was observed in 12 of 12 conventional adenomas with
high-grade dysplasia compared with 60 of 79 with low grade dysplasia (100% vs 76%; p=0.065).
We were unable to demonstrate a significant association between conventional adenoma size or
site and mismatch repair deficiency. All (4/4 or 100%) of the serrated polyps demonstrating
mismatch repair deficiency were traditional serrated adenomas from a single family. Diagnostic
testing of adenomas in suspected Lynch syndrome families is a useful alternative in cases where
cancers are unavailable. The overwhelming majority of conventional adenomas from mutation
carriers show loss of mismatch repair protein expression concordant with the underlying germline
mutation.
Introduction
Lynch syndrome is an inherited disorder of deficient DNA mismatch repair which
predisposes to a high risk of young-onset colorectal cancer as well as cancers at extra-
colonic sites. Colorectal cancers in Lynch syndrome are thought to develop via the common
adenoma-carcinoma developmental pathway with few exceptions1–3. The risk of malignant
transformation in conventional adenomas in general has traditionally been associated with
features such as size (larger adenomas are more likely to undergo transformation), dysplasia
(risk of transformation varies directly with the grade of dysplasia), and the presence of
advanced features (adenomas with villous components are considered to be of higher risk
than adenomas without this morphological feature)4. Consistent with a high risk of
malignant transformation, conventional adenomas arising in Lynch syndrome have also been
reported to more frequently demonstrate villous components and high-grade dysplasia, and
are thought to be larger than those in the general population5. In addition, further reports
have suggested that adenomas from mismatch repair mutation carriers include flat
appearance, and rapid growth6. Adenomas are relatively uncommon before age 50, in both
Lynch syndrome mutation carriers1, 5 and in the general population7. Although Lynch
syndrome patients are thought to develop adenomas at a similar rate as, and in a similar
spontaneous manner to, the general population, Lynch syndrome adenomas once
established, are more likely to undergo malignant conversion, and to be located in the
proximal colon5, 6. It is likely that micro-adenomas in Lynch syndrome mutation carriers do
not remain dormant for many years as is likely to be the case for the general population5.
The demonstration of mismatch repair deficiency in adenomas from mutation carriers points
to establishment in an early premalignant phase during colorectal cancer development.
Lynch syndrome can be difficult to diagnose on clinical criteria because there are no
phenotypic signs in the individual such as polyposis8. In addition, family history is not
always available, nor is it always of a configuration that would alert the clinical team to
Lynch syndrome. Today, screening for Lynch syndrome can be achieved through
immunostaining for mismatch repair proteins in a spectrum of Lynch syndrome-associated
cancers including those of the colorectum, but it remains unclear if screening of colonic
adenomas is of value for the idenitification of patients with Lynch syndrome. Screening of
early-onset adenomas for mismatch repair deficiency in order to diagnose Lynch syndrome
in the population has yielded disappointing results9, suggesting that more focused testing
should be evaluated. Not all Lynch syndrome adenomas found in mismatch repair mutation
carriers show loss of immunostaining, and there is considerable variation in the literature
about the frequency of loss of mismatch repair protein expression in this setting8, 10–13. In
this large case series of 109 polyps from 69 proven mismatch repair mutation carriers, we
demonstrate that the range of adenoma types in which mismatch repair expression loss can
be demonstrated is considerably more diverse than has been previously thought.
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Patients described in this report were enrolled in the Australasian Colorectal Cancer Family
Study14., The had institutional review board approval under the policies and procedures of
the Colon Cancer Family Registry for recruitment of participants and protocols for carrying
out research projects. Germline mutation in MLH1, MSH2, MSH6 or PMS2 had been
determined as previously reported15. Patients were selected on the basis of being a proven
mismatch repair gene mutation carrier and having undergone a polypectomy from which
tissue blocks were available. All polyps underwent a standard review by one specialist
gastrointestinal pathologist (JRJ, NIW or CR) blinded to the mismatch repair
immunohistochemistry results of each polyp. Polyps were assessed for histological sub-type,
reported size (where available from endoscopy report), site in the colorectum (where
known), villous component, and grade of dysplasia. All polyps had been tested by
immunohistochemistry (immunohistochemistry) for the four mismatch repair proteins
MLH1, MSH2, MSH6 and PMS2 as previously described16 using a Dako Cytomation
automated staining machine, and visual assessment. Polyps which demonstrated protein loss
were designated mismatch repair deficient. In addition, microsatellite instability testing
using a panel of 10 markers (incorporating the standard National Cancer Institute panel) was
also carried out as described in a previous report 16 on 66 conventional adenomas and 14
serrated polyps. MLH1 methylation testing was performed as reported previously2, 16 on
four serrated polyps with MLH1 immunodeficiency to determine whether loss of mismatch
repair in these lesions was due to a somatic methylation event17. Somatic BRAF c.1799T>A
(p.V600E) mutation testing was undertaken on all serrated polyps as described in previous
reports2, 16 to determine whether serrated lesions in mismatch repair mutation carriers
develop via the same pathway observed in the general population. Statistical analysis was
carried out using Statistical Package for Social Sciences (SPSS version 19.0 for Macintosh).
Contingency tables were assessed using Fisher's exact test. Differences between means were
assessed using a student’s t-test. To test for equality of the variance between groups
probability plots and an F-test were used. All reported statistical tests were two-sided and P-
values of < 0.05 were considered statistically significant.
Results
Polyps
We examined 109 polyps from 69 proven mutation carriers (35 females and 34 males)
arising in 49 Lynch syndrome families (14 carried a germline mutation in MLH1, 26 in
MSH2, 6 in MSH6 and 3 in PMS2). Of 109 polyps, 94 were conventional adenomas
comprising 65 tubular, 28 tubulovillous and 1 villous adenoma. Of the conventional
adenomas, 6/64 (10%) tubular adenomas demonstrated high-grade dysplasia compared with
6/26 (23%) tubulovillous adenomas (p=0.098). The average age at polypectomy for each
polyp studied was 49 ± 12 SD years (ranging from 22 to 89 years). The average age at
polypectomy for tubulovillous adenomas (47 ± 15 yrs SD) was significantly younger than
the age at polypectomy for tubular adenomas (53 ± 11 yrs SD) (p=0.032). The remaining 15
polyps were serrated polyps comprising 5 microvesicular hyperplastic polyps, 5 sessile
serrated adenomas/polyps and 5 traditional serrated adenomas18. The average age at which
serrated polyps were removed was 42 ± 7 yrs SD, significantly younger than the average age
at removal of conventional adenomas at 51 ± 12.4 yrs SD (p=0.006). A summary of polyp
characteristics is shown in Table 1.
Mismatch Repair Expression Loss
Overall, loss of mismatch repair expression was observed in 78/109 polyps (72%). Seventy-
four of 94 confirmed conventional adenomas (79%) from mismatch repair mutation carriers
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showed loss of expression of mismatch repair proteins. An example of expression loss in a
low-grade ademoma is shown in Figure 1. These included 34/37 (92%) from MLH1
mutation carriers, 34/44 (77%) from MSH2, 4/11 (36%) from MSH6, and 2/2 (100%) from
PMS2 mutation carriers. No statistical difference in patient ages at the time of polypectomy
between mismatch repair deficient and proficient adenomas was observed (49 ± 12 yrs SD
vs 50 ± 11 yrs SD; p=0.82). High-level microsatellite instability results were concordant
with mismatch repair protein loss results in 63/66 (95.6%) evaluable conventional adenomas
and 14/14 (100%) evaluable serrated polyps. Microsatellite instability was detected more
frequently in tubulovillous (95%) than in tubular (76%) adenomas but the difference failed
to reach statistical significance (p=0.09). There was no significant difference between the
detection rate of markers BAT26 and BAT25 (p=0.69). In all instances where mismatch
repair protein was absent, loss of expression was consistent with the underlying germline
mutation, and was continuously absent or occasionally reduced in the lesion. Reduced
pattern expression loss of MLH1 was observed in 4 adenomas. Three arose in a single 68
year old male mutation carrier with an MLH1 splicing mutation [c.790+2dupT r.
[678_790del, 678_884del] p.?]. A second patient, a 43 year old male, also a splicing
mutation carrier in MLH1 [c.1559-2A>T r.spl? p.?] showed reduced intensity of
immunolabelling for MLH1 and complete loss of PMS2 expression. (Figure 2)
Site and Size
Site was able to be determined for 73 conventional adenomas (38 proximal and 35 distal).
Adenomas overall were significantly smaller in the distal colorectum compared with those
derived from the proximal colon (average size 4.89 mm vs 8.11 mm; p=0.004). When site
was considered, there was no difference between the prevalence of mismatch repair deficient
adenomas in the proximal colon (31/38) and the distal colorectum (30/35) (82% vs 86%;
p=0.76). Similarly, size did not appear to play a major role in determining whether an
adenoma would demonstrate loss of mismatch repair expression. Thirty-nine of 55
adenomas (71%) less than 10 mm in size demonstrated loss of mismatch repair protein
compared with 13/17 (76%) of polyps 10 mm or greater in size (p=0.76). Further, 28 of 35
(80%) adenomas less than 5 mm in size also showed loss of mismatch repair proteins. The
smallest mismatch repair deficient adenomas were 2mm in size (n=6).
High-grade Dysplasia and Villous Component
Mismatch repair protein expression was lost in 27 of 29 adenomas with a villous component
compared with 47 of 65 adenomas without this feature (93% vs 73%; p=0.028). Adenomas
with high grade dysplasia were more likely to demonstrate loss of mismatch repair protein,
with every high grade adenoma demonstrating mismatch repair deficiency (12/12) compared
to 60/79 low grade adenomas (100% vs 76%), however the results did not attain statistical
significance (p=0.065). Adenomas with high-grade dysplasia and those with a villous
component were equally likely to arise from either side of the colon. Adenomas with villous
component were significantly larger than those with out this feature (6 ± 4.4 mm SD vs 12 ±
11.9 mm SD; p=0.034). Detailed results for conventional adenomas are shown in Table 2.
Serrated Lesions
Fifteen serrated polyps arising in mismatch repair mutation carriers were examined for
mismatch repair deficiency, and 4 (27%) showed mutation-appropriate loss of expression
(Table 3, Figure 3). Of these, 3 were able to be tested for microsatellite instability and all 3
showed high-levels commensurate with mismatch repair deficiency. All four were
traditional serrated adenomas and all arose in MLH1 mutation carriers from a single family.
The family which has been previously reported elsewhere, had a serrated neoplasia
predisposition segregating independently of the MLH1 mutation2. None of three MLH1-
deficient serrated polyps demonstrated MLH1 methylation or somatic BRAF c.1799T>A
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(p.V600E) mutation. DNA from a fourth lesion failed to amplify after multiple attempts.
Somatic BRAF c.1799T>A (p.V600E) mutation was observed in 3/5 microvesicular
hyperplastic polyps (60%), 3/4 evaluable sessile serrated adenomas/polyps (75%), and 0/3
traditional serrated adenomas.
Discussion
We examined the value of mismatch repair deficiency as a screening test for Lynch
syndrome in a large series of conventional adenomas and a smaller number of serrated
polyps derived from proven mismatch repair mutation carriers, and found that a diverse
range of lesions may be useful for this purpose. Though the majority of previous studies find
evidence of mismatch repair deficiency in at least some adenomas in mismatch repair
mutation carriers12, 19–22, some studies have suggested that it is only worthwhile testing
large, proximal adenomas exhibiting high-grade dysplasia10 while others report a greater
proportion of mismatch repair deficient adenomas from among smaller and distal lesions1,8.
In our series, the overwhelming majority of conventional adenomas in mutation carriers
(79%) showed evidence of mismatch repair deficiency. In common with previous reports1,8,
we found mismatch repair deficiency convincingly demonstrated in small lesions (as small
as 2 mm)1, as well as adenomas from the distal colorectum8. There is general agreement on
the direct relationship between high-grade dysplasia and evidence of mismatch repair
deficiency1, 6, 8, 19, but the size of a mismatch repair deficient adenoma can vary greatly
from 2mm upwards1.
An important feature present in mismatch repair deficient conventional adenomas from
proven mutation carriers was having a villous component. There was also a strong trend for
an association between high-grade dysplasia and mismatch repair deficiency. All high-grade
adenomas and 93% of villous adenomas demonstrated mismatch repair deficiency. A
previous study of proven mutation carriers (15 individuals with 44 adenomas) also showed
this finding8. A further study involving 31 adenomas from 22 mutation carriers found that
15 of 16 high-grade adenomas showed mutation-appropriate loss of mismatch repair, and the
remaining adenoma had heterogeneous expression loss10. Taken together, these observations
suggest that firstly, high-grade adenomas, irrespective of size or site, represent the most
likely lesions in which to screen for Lynch syndrome, and second, that a high-grade lesion
that is mismatch repair proficient decreases the likelihood that Lynch syndrome will be
diagnosed. Similarly, adenomas with a villous component are also likely to return a result of
mismatch repair deficiency in mutation carriers. Patients with Lynch syndrome also
developed conventional adenomas which did not show loss of staining13. Notable among
these, as would be expected therefore, none had high-grade dysplasia and very few
demonstrated a villous component. Though it could be postulated that there are two different
populations of conventional adenomas found in mismatch repair mutation carriers, another
explanation for these observations is that mismatch repair deficiency accelerates
progression5.
A previous report has suggested that the gene involved in mismatch repair mutation carriers
varies in its capacity to demonstrate loss of expression in conventional adenomas, with
MLH1 loss most readily, and MSH6 loss least readily demonstrated8. Our results have also
followed this pattern, with over 90% of adenomas from MLH1 mutation carriers
demonstrating loss in contrast to 36% of MSH6 mutation carriers. Recent studies have
suggested that the Lynch syndrome phenotype is relatively attenuated in MSH6 mutation
carriers23, and this may account for a more indolent progression of adenomas in these
individuals. In contrast to our findings, another report suggested there was a low detection
rate in MLH1 mutation carriers due to heterogeneous staining12. Though heterogeneous
staining was present in our series, the number of lesions demonstrating this was very small,
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and was related to a splicing mutation which may produce a heterogeneous population of
mismatch repair proteins. Loss of expression in the majority of adenomas was complete
suggesting rapid clonal expansion as a result of mismatch repair expression loss. In 2 cases,
mismatch repair protein loss was not accompanied by microsatellite instability. Both of
these lesions were tubular adenomas, with low grade dysplasia; one was 2 mm and the other
7 mm in size. The lack of evidence for microsatellite instability therefore may be related to a
lower proliferative capacity. In a further case, microsatellite instability was present in a
tubular adenoma which showed normal staining of four mismatch repair proteins. This
patient carried a missense mutation in MLH1 c.1865C>T p.Pro622Leu and this mutation
may have produced a protein with immunoreactivity to an MLH1 antibody. Interestingly, we
found that deficiency of mismatch repair proteins was as common in adenomas from the
distal colorectum as it was in those from the proximal colon. However, it is well established
that colorectal cancers in Lynch syndrome are more consistently found in the proximal colon
in5, 24–26, and this suggests that the progression in the proximal colon may be more rapid as
has been suggested by other authors6. Other possibilities include differential site exposure to
carcinogens in the setting of mismatch repair haploinsufficiency, as well as ease of removal
of distal precursor lesions.
In this study, 15 serrated polyps from mismatch repair mutation carriers were also analysed
using immunostaining for mismatch repair deficiency. Loss of expression commensurate
with the germline mutation was seen in a subset of these polyps. Interestingly, of 5
traditional serrated adenomas, 4 showed appropriate expression loss, and though overall the
detection rate using serrated polyps in general was decreased when compared to
conventional adenomas, the majority of traditional serrated adenomas showed mutation-
appropriate loss of expression involving MLH1. Serrated polyps in Lynch syndrome27, 28
may arise either spontaneously, or in families segregating two genetic predispositions2. In
this study, all mismatch repair deficient serrated polyps arose in such a family2, and
therefore it is difficult to draw definitive conclusions regarding the usefulness of mismatch
repair immunohistochemistry in the diagnosis of Lynch syndrome. There have been
previous reports of expression loss in serrated polyps in mismatch repair mutation carriers.
Pino et al reported findings for immunostaining of 5 hyperplastic polyps from 3 patients
with Lynch syndrome8. In two patients with MSH2 mutations, each had a “pure”
hyperplastic polyp where the MSH2 staining had been preserved. In a third patient with an
MLH1 mutation, three lesions were described as “mixed polyps containing elements of
hyperplastic polyp and tubular adenoma”, with expression loss of MLH1 confined to areas
with cytological dysplasia. In this study, we were not able to assess whether other mismatch
repair proteins were lost in serrated polyps from mutation carriers due to lack of these
lesions from appropriate individuals. Loss of MSH2 expression for example in a dysplastic
serrated polyp would increase confidence that an individual harbored a Lynch syndrome
mutation.
The major strength of this study relates to numbers of cases with known germline mutations.
Our study includes 69 proven mutation carriers from the Australasian site of the Colon
Cancer Family Registry14, and as such represents the largest series reported so far. Two
previous publications examined 44 adenomas from 15 proven mutation carriers8 and 31
adenomas from 22 mutation carriers respectively10. Additional publications have not
definitively identified substantive numbers of their subjects as mutation carriers, relying
instead on features such as family history of cancer. A limitation of the study is that it does
not provide any information on the usefulness of adenoma immunohistochemistry as a
screening test for young onset population-based adenomas. A previous study has suggested
that an approach using microsatellite instability as a screening test is likely to produce a low
yield9. The increasing recognition of the role of family history in determining risk has lead
to increased colorectal cancer screening. With increased screening, there will be less
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colorectal cancer available Lynch syndrome screening8. From our study, we conclude that
immunohistochemical mismatch repair testing of adenomas from patients in suspected
Lynch syndrome families is a useful alternative in cases where spectrum cancers are
unavailable. The overwhelming majority of conventional adenomas from proven mutation
carriers showed appropriate loss of mismatch repair proteins, and this was significantly
associated with a villous component and a trend to high-grade dysplasia.
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Example of loss of expression of mismatch repair proteins in a tubular adenoma with low
grade dysplasia from a patient with germline mutation in MLH1. Figure shows loss of
MLH1 (A) and PMS2 (B) in adenoma cells.
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H&E staining (A), immunohistochemistry for MLH1 (B) and PMS2 (C) in a patient with a
germline splicing mutation in MLH1 showing heterogeneous loss of expression of MLH1
and complete loss of expression of PMS2 in adenoma cells.
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A traditional serrated adenoma in a patient with germline mutation in MLH1 showing loss
of expression of the correponding protein in adenoma cells (A: H&E; B: MLH1
immunohistochemistry).
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